Novotech Global Report: Robust Phase 1 Trial Growth Across Asia Pacific
SYDNEY, AU, Feb 10, 2023 - (ACN Newswire) - Novotech, the leading Asia Pacific centred biotech CRO, has published a new global report on Phase 1 trial activity including current metrics on fast growth regions and therapeutic areas. The data analysis found that Asia Pacific has been the fastest-growing region for Phase 1 trials in the last ten years, reaching a share of 58% in 2022, with China leading the Phase I trials globally.
According to the report, titled "Phase I Global Clinical Trial Landscape - Focus on Asia Pacific", in 2022 Asia Pacific accounted for a 58% share of the approximately 3,600 Phase I trials initiated globally in 2022. The report found that Asia Pacific has been the fastest growing region for Phase 1 trials in the last ten years with a 10Y CAGR of 18%. Between 2018 and 2022, the region has had consistent performance and has been maintaining its majority share since 2018, with a peak of 61% share achieved in the year 2021. Mainland China, Australia, South Korea, Japan and India were the top five Asian locations, and together contribute over 50% of the global phase I trials.
One of the key reasons why Asia Pacific is in demand is that it has the shortest patient enrolment duration and fastest recruitment rate. Asia Pacific region has a much wider patient base which expedites the patient time recruitment process and shortens the trial duration enabling initiation and completion of trials.
The report found that Asia Pacific also leads phase I trials across the top therapeutic areas. Oncology, infectious disease, CNS, cardiovascular and metabolic disorders are the top therapeutic areas of Phase I trials across the top Asian locations of China, Australia, South Korea, Japan and India. Of all the five locations put together, China occupies the major share (>80%) of phase I trials in all the top therapeutic areas considered together.
View "Phase I Global Clinical Trial Landscape - Focus on Asia Pacific", the new report by Novotech, on this link: https://tinyurl.com/novotech-global-report
See the report for Phase 1 location and therapeutic area analysis including: - IMMUNOMODULATORY THERAPY - IMMUNO-ONCOLOGY - ADOPTIVE CELL THERAPY - ALLOGENIC, AUTOLOGOUS, STEM CELL AND REGENERATIVE MEDICINE - DNA AND RNA - VACCINES - MULTI-SPECIFIC MONOCLONAL ANTIBODY - MICROBIOME
Cell & Gene
The latest data also shows Asia Pacific is the fastest-growing region globally for cell & gene therapy trials representing more than a third of all cell & gene studies, with China leading in the region. The region already accounts for over a third of cell & gene therapy trial activity and shows a nearly 50% faster growth rate in cell & gene therapy trials compared to ROW between 2016 and 2021. China shows a 15% faster growth rate than the ROW. After oncology, the majority of cell & gene trials are in infectious diseases, CNS, and cardiovascular diseases. In addition, the Asia Pacific is the leading location globally for CAR-T trials with China attracting ~60% of all CAR-T trials globally between 2015-2022.
European expansion - global footprint
Novotech offers a unique and unparalleled suite of early to late-phase CRO services across Europe and the US, with a specialist focus on Asia Pacific where the company has built a reputation for delivering high-quality expedited clinical trials. Novotech recently acquired EastHORN, a European CRO with clinical, medical and regulatory expertise in multiple strategically important locations across the continent. The acquisition is part of Novotech's global expansion program in Europe and the US.
Award recognition
Novotech has recently been benchmarked as a top 10 CRO among the world's leading CROs, has been awarded the Asia-Pacific Cell & Gene Therapy Clinical Trials Excellence award and selected for the Asia-Pacific Contract Research Organization Company of the Year Award. The company has signed 45 Leading Site Partnership agreements over the last 3 years.
About Novotech (Novotech-CRO.com)
Novotech is internationally recognized as the leading Asia Pacific centred biotech Contract Research Organization (CRO) with global execution capabilities. Novotech is a clinical CRO with labs, phase I facilities, drug development consulting services and FDA regulatory expertise and has experience in over 3,700 pre-clinical and clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. Novotech is positioned to serve biotech clients conducting clinical trials in Asia Pacific, the US and Europe. Novotech has over 2700 staff working across offices in 20 geographies. For more information visit https://novotech-cro.com/contact
Media Contact David James E: communications@novotech-cro.com AU: +61 2 8218 2144 USA: +1 415 951 3228 Asia: +65 3159 3427
Source: Novotech Health Holdings Pte Ltd Sectors: BioTech, Healthcare & Pharm, Clinical Trials
Copyright ©2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
Latest Release
 Fujitsu and Tokai National Higher Education and Research System utilize AI to accelerate clinical research and tackle 'drug loss' in Japan May 23, 2025 17:29 JST
|  Lockheed Martin and Fujitsu Strengthen Japan Industry Collaboration with SPY-7 Supplier Selection and Strategic Agreements May 23, 2025 13:36 JST
|  NIED, Fujitsu, SDS and Mitsubishi Electric sign joint research agreement to advance Japan Disaster Charter operational framework May 23, 2025 13:35 JST
|  Honda Expands Production Capacity by Adding New Production Line at Fourth Motorcycle Plant in India May 23, 2025 12:17 JST
|  Honda Reaches 500 Million-Unit Milestone in Cumulative Global Motorcycle Production May 23, 2025 11:32 JST
|  Five Toyota Group Companies to Accelerate Skill Development and Innovation in AI and Software May 23, 2025 10:51 JST
|  MHI Conducts Flight Test for Hybrid-Type Medium-Sized UAV May 22, 2025 13:35 JST
|  Eisai Demonstrates Commitment to Oncology Innovation at ASCO 2025 May 21, 2025 15:00 JST
|  New RAV4 Makes World Premiere in Japan May 21, 2025 14:09 JST
|  Naoris Protocol Begins Token Sale for First Post-Quantum Infrastructure Layer May 21, 2025 14:00 JST
|  MHI Marine Machinery Begin Demonstration Testing of Methane Oxidation Catalyst System for Marine LNG Engines May 20, 2025 13:51 JST
|  MHI Launches 'Prismo,' a New Brand Eco-Friendly Next-Generation AGT May 19, 2025 16:14 JST
|  Eisai Satisfies All-Case Surveillance Requirement for Anticancer Agent Remitoro May 16, 2025 17:21 JST
|  Premiere of New bZ Woodland BEV Focused on Driving Performance and Spaciousness in North America May 16, 2025 16:35 JST
|  Mitsubishi Heavy Industries Activates New Driving Force for Data Center Business in the United States May 16, 2025 15:43 JST
|  MHI Thermal Systems Receives JSRAE Technology Award May 15, 2025 20:08 JST
|  Honda and Quemix Co-develop a New, World's First Quantum State Readout Technology May 15, 2025 13:37 JST
|  Mitsubishi Electric Building Solutions Launches a New Projection-type Hall Lantern for Overseas Markets May 15, 2025 11:00 JST
|  MHI Starts Operation of New CO2 Capture Pilot Plant at KEPCO's Himeji No.2 Power Station May 14, 2025 16:50 JST
|  Making Anime More Interesting and Taking it into the Future, Launch of Three New Projects May 14, 2025 11:00 JST
|
More Latest Release >>
|